| Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma J Krejcik, T Casneuf, IS Nijhof, B Verbist, J Bald, T Plesner, K Syed, K Liu, ... Blood, The Journal of the American Society of Hematology 128 (3), 384-394, 2016 | 929 | 2016 |
| Using transcriptomics to guide lead optimization in drug discovery projects: Lessons learned from the QSTAR project B Verbist, G Klambauer, L Vervoort, W Talloen, Z Shkedy, O Thas, ... Drug discovery today 20 (5), 505-513, 2015 | 107 | 2015 |
| VirVarSeq: a low-frequency virus variant detection pipeline for Illumina sequencing using adaptive base-calling accuracy filtering BMP Verbist, K Thys, J Reumers, Y Wetzels, K Van der Borght, W Talloen, ... Bioinformatics 31 (1), 94-101, 2015 | 70 | 2015 |
| A web application for sample size and power calculation in case-control microbiome studies F Mattiello, B Verbist, K Faust, J Raes, WD Shannon, L Bijnens, O Thas Bioinformatics 32 (13), 2038-2040, 2016 | 68 | 2016 |
| Discovery and pharmacological characterization of JNJ-64619178, a novel small-molecule inhibitor of PRMT5 with potent antitumor activity D Brehmer, L Beke, T Wu, HJ Millar, C Moy, W Sun, G Mannens, V Pande, ... Molecular cancer therapeutics 20 (12), 2317-2328, 2021 | 55 | 2021 |
| Immunomodulatory effects and adaptive immune response to daratumumab in multiple myeloma J Krejcik, T Casneuf, I Nijhof, B Verbist, J Bald, T Plesner, K Liu, ... Blood 126 (23), 3037, 2015 | 45 | 2015 |
| 5-Sulfonyl-benzimidazoles as selective CB2 agonists BMP Verbist, MAJ De Cleyn, M Surkyn, E Fraiponts, J Aerssens, ... Bioorganic & medicinal chemistry letters 18 (8), 2574-2579, 2008 | 41 | 2008 |
| Performance assessment of the Illumina massively parallel sequencing platform for deep sequencing analysis of viral minority variants K Thys, P Verhasselt, J Reumers, BMP Verbist, B Maes, J Aerssens Journal of virological methods 221, 29-38, 2015 | 34 | 2015 |
| 5-Sulfonyl-benzimidazoles as selective CB2 agonists-Part 2 HJM Gijsen, MAJ De Cleyn, M Surkyn, GRE Van Lommen, BMP Verbist, ... Bioorganic & medicinal chemistry letters 22 (1), 547-552, 2012 | 30 | 2012 |
| Design and synthesis of novel type VI-like β-turn mimetics. Diversity at the i+ 1 and the i+ 2 position WM De Borggraeve, BMP Verbist, FJR Rombouts, VG Pawar, WJ Smets, ... Tetrahedron 60 (50), 11597-11612, 2004 | 29 | 2004 |
| BIGL: Biochemically Intuitive Generalized Loewe null model for prediction of the expected combined effect compatible with partial agonism and antagonism K Van der Borght, A Tourny, R Bagdziunas, O Thas, M Nazarov, H Turner, ... Scientific Reports 7 (1), 17935, 2017 | 22 | 2017 |
| ViVaMBC: estimating viral sequence variation in complex populations from illumina deep-sequencing data using model-based clustering B Verbist, L Clement, J Reumers, K Thys, A Vapirev, W Talloen, Y Wetzels, ... BMC bioinformatics 16, 1-11, 2015 | 18 | 2015 |
| Stereoselective intramolecular Diels–Alder reactions of 3-alkenyl (oxy)-2 (1H)-pyrazinones WM De Borggraeve, FJR Rombouts, BMP Verbist, EV Van der Eycken, ... Tetrahedron letters 43 (3), 447-449, 2002 | 14 | 2002 |
| Integrating high-dimensional transcriptomics and image analysis tools into early safety screening: proof of concept for a new early drug development strategy BMP Verbist, GR Verheyen, L Vervoort, M Crabbe, D Beerens, ... Chemical research in toxicology 28 (10), 1914-1925, 2015 | 13 | 2015 |
| Structure based design of simplified analogues of insect kinins L Kamoune, WM De Borggraeve, BMP Verbist, JV Broeck, GM Coast, ... Tetrahedron 61 (40), 9555-9562, 2005 | 11 | 2005 |
| Pharmacodynamic relationship between natural killer cells and daratumumab exposure in relapsed/refractory multiple myeloma T Casneuf, XS Xu, HIII Adams, A Axel, B Verbist, K Liu, I Khan, T Ahmadi, ... Haematologica 101, 87-88, 2016 | 10 | 2016 |
| A joint modeling approach for uncovering associations between gene expression, bioactivity and chemical structure in early drug discovery to guide lead selection and genomic … N Perualila-Tan, A Kasim, W Talloen, B Verbist, HWH Göhlmann, ... Statistical applications in genetics and molecular biology 15 (4), 291-304, 2016 | 9 | 2016 |
| Pharmacological characterization of JNJ-75276617, a menin-KMT2A inhibitor, as targeted treatment for KMT2A-altered and NPM1-mutant acute leukemia MC Kwon, O Querolle, X Dai, JW Thuring, T Verhulst, A Marien, D Goffin, ... Blood 140 (Supplement 1), 5928-5929, 2022 | 8 | 2022 |
| QQ-SNV: single nucleotide variant detection at low frequency by comparing the quality quantiles K Van der Borght, K Thys, Y Wetzels, L Clement, B Verbist, J Reumers, ... BMC bioinformatics 16, 1-14, 2015 | 8 | 2015 |
| Analyzing magnetic bead QuantiGene® Plex 2.0 gene expression data in high throughput mode using QGprofiler B Verbist, E Adriaensen, V Keersmaekers, D Putri, M Crabbe, M Derks, ... BMC bioinformatics 20, 1-10, 2019 | 6 | 2019 |
